Zucker Diabetic Fatty Rat
Zucker Diabetic Fatty Rat - Related Videos
11:08
The Use of Gas Chromatography to Analyze Compositional Changes of Fatty Acids in Rat Liver Tissue during Pregnancy
0 Views •
Cited by 71 •
2014
Pregnancy leads to significant changes to the fatty acid composition of maternal tissues. Lipid profiles can be obtained via gas chromatography to allow identification and quantification of fatty acids in individual lipid classes among rats fed various high and low fat diets during pregnancy.
05:45
Rapid Determination of the Thermal Nociceptive Threshold in Diabetic Rats
0 Views •
Cited by 10 •
2012
Here, we describe a rapid reliable and simple procedure to determine the lowest temperature at which rats or mice show nocifensive behavior, i.e. the thermal nociceptive threshold (TNT). This method applies a slowly increasing thermal stimulus allowing precise and reproducible estimation of TNTs with minimum, if any, stress to the animals.
06:03
Quantification of Endothelial Fatty Acid Uptake using Fluorescent Fatty Acid Analogs
0 Views •
2025
This protocol details an in vitro assay for measuring cellular lipid uptake in endothelial cells upon stimulation with BODIPY-C12 and BODIPY-C16 fluorescent analogs of long-chain and very long-chain saturated fatty acids. This method is efficient and adaptable to other cell types, offering a useful approach for studying lipid metabolism.
10:27
An Ultrasonic Tool for Nerve Conduction Block in Diabetic Rat Models
0 Views •
Cited by 3 •
2017
This work presents the methodology of applying high intensity-focused ultrasound to block the action potentials of diabetic neuropathic nerves.
07:04
High-Intensity Focused Ultrasound for Blocking Nerve Action Potentials in a Diabetic Rat Model
0 Views •
2025
Source: Lee, Y. F., et al. An Ultrasonic Tool for Nerve Conduction Block in Diabetic Rat Models. J. Vis. Exp. (2017)This video demonstrates the use of high-intensity focused ultrasound (HIFU) to block action potentials from the sciatic nerve to the gastrocnemius muscle in a diabetic rat model. Upon delivering the HIFU beam to the nerve, a decrease in muscle signal confirms HIFU's potential as a non-invasive therapy for diabetic neuropathic pain relief.
FAQs
The leptin-receptor mutation disrupts satiety signaling, so affected rats show hyperphagia, meaning increased food intake. That excess intake promotes obesity and contributes to insulin resistance, in which tissues respond less effectively to insulin. This sequence makes the model useful for examining how altered appetite regulation can initiate downstream metabolic disease.
Insulin resistance does not by itself explain persistent hyperglycemia in susceptible ZDF rats. As disease progresses, pancreatic beta-cell function declines, reducing the capacity to maintain glucose control. Studying this transition allows investigators to distinguish early metabolic dysfunction from later beta-cell failure and to examine why diabetes becomes sustained.
Obesity, insulin resistance, and beta-cell dysfunction form an interconnected progression rather than isolated findings. ZDF rats therefore help researchers examine glucose and lipid metabolism together, asking how disturbances in one metabolic domain accompany changes in another. This integrated view is relevant to metabolic syndrome and to the development of diabetes-related complications.
Studies with ZDF rats can follow diabetes progression while assessing glucose and lipid metabolism, rather than relying on a single disease feature. Investigators may use the model to connect metabolic changes with pancreatic beta-cell dysfunction and persistent hyperglycemia. Such disease-focused work helps place treatment effects within the broader course of metabolic disease.
The model supports investigation of complications beyond abnormal blood glucose, particularly vascular and renal disease. Researchers can therefore ask whether metabolic deterioration is accompanied by complications in these organ systems and use those outcomes to study disease mechanisms. This expands ZDF research from diabetes onset to the broader medical consequences of obesity-associated metabolic disease.
Antidiabetic treatments can be evaluated in ZDF rats for their effects on the metabolic abnormalities represented by the model. Responses are especially informative when interpreted against insulin resistance, progressive beta-cell dysfunction, hyperglycemia, and altered lipid metabolism. The model thus provides a preclinical setting for testing therapeutic strategies relevant to human metabolic disease.